कृपया अन्य खोज का प्रयास करें
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Neal S. Walker | 54 | 2012 | Co-Founder, President, Chairman & Interim CEO |
Marco Colonna | - | 2020 | Member of the Scientific Advisory Board |
Michael E. Weinblatt | - | 2020 | Member of the Scientific Advisory Board |
Philip J. Mease | - | 2021 | Member of Scientific Advisory Board |
Stanley B. Cohen | - | 2020 | Member of the Scientific Advisory Board |
James G. Krueger | - | 2020 | Member of the Scientific Advisory Board |
Christopher P. Molineaux | 58 | 2014 | Lead Independent Director |
Andrew Newman Schiff | 59 | 2017 | Independent Director |
Guy F. Webster | - | - | Member of Advisory Board |
Mark Bradshaw | 71 | - | Member of Advisory Board |
Leslie Baumann | - | - | Member of Advisory Board |
Pearl E. Grimes | - | - | Member of Advisory Board |
Klaus PJ Theobald | 68 | - | Member of Advisory Board |
Kenneth Beer | - | - | Member of Advisory Board |
William D. Humphries | 58 | 2016 | Independent Director |
Anand Mehra | 48 | 2014 | Independent Director |
James J. Leyden | 83 | - | Member of Advisory Board |
Bryan M. Reasons | 57 | 2018 | Independent Director |
Andrew L. Ondo | - | - | Member of Advisory Board |
Maxine Gowen | 66 | 2019 | Independent Director |
Andrew Kenneth Williams Powell | 66 | 2017 | Independent Director |
Vincent J. Milano | 60 | 2020 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है